The news flow continues with deals and talk of deals. I want to end this week (will be at home for the holidays Thursday and Friday) with a follow up and then a new idea. 1. SRPT continues to be hated and while it is frustrating I love the hate. Goldman put out of note […]
December 2 Biotech Update
ASH starts soon and the sector needs some more positive news as it is really starting to lag. Outside of the initial election pop it has been pretty bad in terms of relative performance. To be fair, the news outside of the election has been failures and secondaries. Obviously the sector needs more than the […]
A Deep Dive in SRPT Chart!
Sarepta Therapeutics, Inc. (SRPT) -Nasdaq During the past six weeks we had so many stories, with or against SRPT approval, where a 10-million shares short sellers are still traped in this name with a significant loss after the FDA approval, and they are trying nonstop any way or attack to find a way to make […]
October 4 Biotech Update
Today is certainly a better start. It seems that the sector is trading to a certain extent on macro issues with the DB concerns leading to risk on versus risk off action. The sector will always be a victim to large risk off moves, so if the DB situation resolves I would not be surprised […]
September 20 Biotech Update
A little but more news today and there are actually some interesting implications. Yesterday was actually not great in terms of trading given the weakening towards the end of the day but with more positive news today we should see the rally continue. Again, if it struggles on the back of positive news yesterday and […]
September 19 Biotech Update
Another slow news start to the week. Without anything positive or negative to drive trading, I suspect we generally move with the market with perhaps some modest outperformance. The trend for the sector has been positive and there is nothing since Friday that should change that underlying tailwind. {Note that is what I wrote before […]
September 14 Biotech Update
The market seems to reversing from the decline yesterday, although not to the same extent of the selloff. This is odd trading in terms of these large swings on little news but it does appear that the sector continues to outperform the market (perhaps more so in the up days than in the down days). […]
We saw some more low volume drift and no real news to break through the summer doldrums, which seems to be in effect. I think this will probably be the rule for the rest of the summer with choppy, low volume trading as the rule punctuated but news filled days that drive the sector (or […]
June 8 Biotech Update
Yesterday was surprisingly good, although so far we have not really had a nice follow through to start today. That being said the rally started to pick up steam later in the day, so perhaps we will follow the same pattern. If we continue to trade well in lieu of the negative news yesterday, then […]
June 7 Biotech Update
Today is going to be a real test of the sector with all the negative news that came out. I am sure some will try to call this the ASCO hangover but any selling today has little to do with ASCO. The sector has had a good run and I would not be surprised to […]
June 2 Biotech Update
I missed a day but not much happened. The sector continues to do well and it seems to be slowly turning sentiment around. The one negative (or perhaps positive) is that the ISI traders noted that there is still not buying demand and the move seems to be driven by a lack of sellers and […]
Cup O’ Joe – May SRPT Edition
***Joe Gantoss relies on knowing more, either through technical analysis & charts or DD & research.*** Well, SRPT has delayed their decision past the PDUFA, destroying the weekly out-of-the-money (OTM) options traders counting on a decision. I debated making a play, but ultimately I was not comfortable. But that trade is over, where do we […]
May 25 Biotech Update
The market continues higher and the sector with it. We seem to be moving away from the previous lows with broader participation with SMID and large caps. This market continues to be hated and I suspect people are still underinvested in healthcare. This all makes me marginally more bullish in the near term even though […]
Eteplirsen: Reasonable Evidence of Efficacy
The Adcom is over and Eteplirsen was voted down. A final decision still remains for approval. Much was discussed in the Adcom, the key arguments were over the following: 1. Adequacy of dystrophin creation. 2. Efficacy of 201/202 Trial vs Historical Controls Both are intertwined. Adequacy of dystrophin creation: FDA had little faith in […]
April 27 Biotech Update
This week seems to have started like last week. I think it was actually last Tuesday that the sector suddenly took a dive on no real news and yesterday was certainly not a good day. It remains to be seen if this weakness will continue as we are entering into earnings that could help the […]
April 21 Biotech Update
I think the best description of the sector is listless and uncertain. The price action has been mixed but more than anything else, there has been a significant lack of volume. No one wants to buy or sell biotechs and so they have been drifting with some good days and some bad days. We are […]
SRPT – Final thoughts ahead of the AdCom
Reaching the decision point… Today is the day we have to make decisions in SRPT position. As has been explained several times in the forum and CRG twitter private feed, the date of the panel is 04/25 and the FDA BD comes two days before the preliminary panel (2 business days), it should be […]
March 22 Biotech Update
It looks like the sector did not fall off a cliff and perhaps has been finding some support. We still have the recurring question of whether this is real buying or simply short covering. As has been the case, I fall in the camp that this is short covering at least among the smaller caps. […]
SRPT – YEAR 4 DATA ANALYSIS
YEAR 4 DATA ANALYSIS Review of Eteplirsen to treat DMD By: @boscaptn, et al. Compiled From SAREPTA Public Data For Week 216 (Year 4) of Study 201/202 for Exon 51 Disclaimer: NO FINANCIAL ADVICE – The Information in this report is provided for education and informational purposes only, without any express or […]
Cup O' Joe – SRPT AdCom
***Our trading analyst Joe Gantoss relies on knowing more, either through technical analysis & charts or DD & research.*** Thesis: Joe has done a lot of research on SRPT. Despite some FDA headwinds, he believes the AdCom will at least be moderately positive for SRPT. But there is some downside risk, so there is […]
